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Abstract
Studying protein O-glycosylation remains an analytical challenge. Different from N-linked
glycans, the O-glycosylation site is not within a known consensus sequence. Additionally, O-
glycans are heterogeneous with numerous potential modification sites. Electron transfer
dissociation (ETD) is the method of choice in analyzing these glycopeptides since the glycan side
chain is intact in ETD, and the glycosylation site can be localized on the basis of the c and z
fragment ions. Nonetheless, new software is necessary for interpreting O-glycopeptide ETD
spectra in order to expedite the analysis workflow. To address the urgent need, we studied the
fragmentation of O-glycopeptides in ETD and found useful rules that facilitate their identification.
By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS
data, we applied the method to glycopeptides generated from various O-glycosylated proteins
including mucin, erythropoietin, fetuin and an HIV envelope protein, 1086.C gp120. The site-
specific O-glycopeptide composition was correctly assigned in every case, proving the merits of
our method in analyzing glycopeptide ETD data. The algorithm described herein can be easily
incorporated into other automated glycomics tools.
INTRODUCTION
O-linked glycosylation typically occurs on serine and threonine residues in a protein, with
the glycan portion bonded to a hydroxyl group on the amino acid’s side-chain.1 Mucin-type
O-glycan is the most commonly seen O-glycosylation form; it contains an α-N-
acetylgalactosamine (GalNAc) core structure.2-3 Recent studies indicate that aberrant
mucin-type O-glycosylation on membrane proteins of tumor cells is closely related to cancer
metastasis, and the tumor-specific glycosylation can be mimicked to develop glycoprotein-
based cancer vaccine.4-5 It is thus a prerequisite to unravel the glycosylation profile on
proteins.
However, O-linked glycopeptide analysis by mass spectrometry (MS) has long been a
tedious task.2, 6 Unlike N-linked glycosylation, no consensus sequence is available to predict
potential O-glycosylation sites; there are eight different basic structures in mucin-type
GalNAc-linked glycans with even more branching and elongations.3, 7 In a typical analysis
workflow, high resolution MS data helps to limit the number of possible candidate
compositions, and MS/MS data are essential for determining the correct glycopeptide
assignment.8-9 Unfortunately, collision-induced dissociation (CID), a readily available
fragmentation method, has the disadvantage that it favors carbohydrate dissociation over
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peptide fragmentation in characterizing O-glycopeptides. While CID data are useful for
inferring the glycan composition, typically one cannot be able to identify the peptide
sequence or the glycosylation site using these data.10-11
Among tools that can generate glycopeptide backbone cleavages including higher energy
collisional dissociation (HCD)12-14, infrared multiphoton dissociation (IRMPD)9, 15-18 and
electron capture dissociation (ECD)17-20, electron transfer dissociation (ETD)21-25 is the
most widely used one and is highly orthogonal to CID in analyzing glycopeptides. Several
groups have employed ETD in large-scale glycopeptide sequencing and O-glycosylation site
identification at the proteome level.26-28
While a number of applications are now published using ETD in glycoproteomics,
automated analysis for O-glycopeptide data is virtually nonexistent. The only reported work
for automated assignment of O-linked glycopeptides involved the usage of Protein
Prospector software to identify glycopeptides bearing O-glycan structures of
SA1-0Hex1-0HexNAc by scoring the CID and ETD spectra.10, 29 Nevertheless, the algorithm
was developed to weight different fragment ion types based on the statistics of peptide
fragmentation rules rather than glycopeptide fragmentation.30-31 Moreover, only O-
glycopeptides with simple glycan compositions could be searched and assigned.
In view of the urgent need to speed data interpretation in glycopeptide analysis, we report
characteristic fragmentation patterns of intact O-glycopeptides in ETD and provide an
algorithm to score ETD spectra of O-linked glycopeptides. Specifically, we show that the
dominant fragment ion type in the glycopeptide sequence may vary with different precursor
ions. In addition, for O-glycopeptide species at 3+ or higher charge state, doubly charged
c2+- and z2+-ion series were frequently recorded in the high m/z half of the spectrum, while
their singly charged counterparts were beyond the spectral mass range. These key features
were incorporated into the design of an algorithm that is specifically optimized for scoring
potential O-glycopeptide candidates against the ETD data. Using our method, site-specific
assignment of O-glycopeptide compositions could be made a highly accurate way. The
algorithm presented here may be readily incorporated into other database search engines and
data analysis tools for analyzing ETD-MS/MS spectra of O-glycopeptides.
EXPERIMENTAL SECTION
Samples and Reagents
Bovine fetuin was purchased from Sigma Aldrich (St. Louis, MO). The HIV envelope
glycoprotein, 1086.C gp120, was expressed in transiently transfected 293T cells and purified
by the Duke Human Vaccine Research Institute (Durham, NC).32 O-linked glycopeptides
from erythropoietin and mucin-5AC were obtained from Anaspec (Fremont, CA) for direct-
infusion MS experiments. Glycerol-free peptidyl-N-glycosidase F (PNGase F) cloned from
Flavobacterium meningosepticum was purchased from New England BioLabs (Ipswich,
MA). Sequencing grade trypsin was supplied by Promega (Madison, WI). Chemical
reagents were of analytical purity or better.
Sample Preparation
Glycoprotein samples of 100 μg were prepared in 100 mM Tris buffer at pH 8. To remove
N-glycans from the glycoprotein, samples were incubated with 2 μL of PNGase F (5000
units/mL) solution at 37 °C overnight. Subsequently, glycoproteins were denatured by 6 M
urea and were treated with 5 mM tris(2-carboxyethyl)-phosphine (TCEP) to reduce the
disulfide bonds. Following reduction, samples were alkylated with 20 mM iodoacetamide
(IAM) at room temperature for 1 h in the dark. Excess IAM was quenched by adding 10 mM
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dithiothreitol (DTT). Before digestion, samples were diluted to decrease the urea
concentration to 1 M. Trypsin was then added to samples at a 1:30 enzyme-to-protein ratio
and the digestion lasted for 18 h at 37 °C. One microliter of formic acid was added to
terminate the reaction and samples were stored at −20 °C until further analysis.
LC-MS/MS
Digested glycoprotein samples were subjected to online LC-MS/MS experiments. Sample
was injected onto a Vydac Capillary C8 column (320 μm i.d. × 10 cm, 300 Ǎ, Micro-Tech,
Vista, CA) coupled to a Thermo Scientific LTQ Velos ion trap mass spectrometer (San Jose,
CA) through a Waters Acquity UltraPerformance UPLC system (Milford, MA). Mobile
phases consisted of solvent A: 99.9% H2O + 0.1% formic acid and solvent B: 99.9%
CH3CN + 0.1% formic acid. The flow rate was set at 7 μL/min. A separation gradient was
employed as follows: 5% solvent B for 5 min, followed by a linear increase to 40% B in 45
min, and then a ramp to 95% B in 10 min. The column was held at 95% B for 10 min and
finally reequilibrated in 5% B for another 15 min. For MS settings, the ESI source had a
source voltage of 2.8 kV and the capillary temperature was 250 °C. Data were obtained in
the positive ion mode. One sample was analyzed in two runs that were set for CID and ETD
experiments, respectively. Following a full MS scan (m/z 500-2000) in the enhanced scan
mode, five most intense ions from the survey scan were sequentially isolated and
fragmented by CID or ETD in a data-dependent fashion. The normalized collision energy
was set at 35% for CID with activation time of 10 ms. The ion-ion reaction time was 90-150
ms for ETD, and supplemental activation was turned on.33 The automatic gain control
(AGC) target value was set at 2×104 for the MS/MS experiment in the linear ion trap, and
the AGC target value was 2×105 for the fluoranthene reagent anions.
Direct-infusion MS/MS
Glycopeptide standards having sequences of GTTPSPVPTTSTTSAP,
GTTPSPVPTTSTTSAP and EAISPPDAASAAPLR (where T and S are residues modified
with N-acetylgalactosamine, GalNAc), respectively, were dissolved in water/methanol
(50:50) with 1% formic acid to a concentration of 500 nM. The prepared solution was
introduced into the mass spectrometer by direct infusion at a flow rate of 3 μL/min in the
positive ion mode. The ESI source was optimized using the following conditions: the spray
voltage was 3.0 kV, capillary temperature was 200 °C and nitrogen carrier gas was 10 psi.
Selected precursor ions in the full MS scan were subjected to both CID and ETD with a 2.5
Da isolation width. The activation time was 30 ms and activation energy was 30% in CID,
while the reaction time in ETD was 100 ms with the maximum injection time of
fluoranthene anions set as 150 ms. Thirty scans, each with 10 microscans, were averaged in
the collection of MS/MS data.
Data Analysis
Glycoproteins used in this study (fetuin and HIV Env glycoprotein) have been well
characterized in the literature regarding their O-glycosylation profiles and O-glycopeptides
with known structures were searched for in the MS and MS/MS data.32, 34-35 Specifically,
glycoproteins were tryptically digested in silico to produce peptides with up to 2 missed
cleavages. Cysteine residues were carbamidomethylated. Theoretical masses of potential O-
glycopeptides were calculated by adding site-specific O-glycan masses to the corresponding
peptide sequences that contain the reported glycosylation sites. Glycopeptide masses were
then converted to theoretical m/z values, which were searched against the full scan mass
spectra with a mass tolerance of 200 ppm. If a peak was matched, the CID-MS/MS spectrum
was interrogated to confirm the presence of oxonium ions [m/z 204 (HexNAc), 292 (SA),
366 (Hex-HexNAc), etc.] and characteristic peaks derived from monosaccharide losses. If
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the CID data was confirmed to be from a glycopeptide, the ETD-MS/MS spectrum of the
same O-glycopeptide was verified manually to analyze its fragmentation patterns in ETD.
Algorithm Performance Test
An in-house program, GlycoPep Scorer, was coded in MATLAB based on the algorithm that
was described below and in Supporting Information. A peak list file was created from each
glycopeptide ETD-MS/MS spectrum and was uploaded to both GlycoPep Scorer and Protein
Prospector (http://prospector.ucsf.edu) for scoring.36 The m/z value and charge state of the
precursor ion were input into each program. The glycoprotein sequence and randomized
decoy sequences were directly entered into Protein Prospector. The same glycopeptide
candidates were also scored by GlycoPep Scorer. Search parameters were set the same for
the two programs. Trypsin was selected as the enzyme and 2 missed cleavage sites were set
as the maximum. Carbamidomethylation was a fixed modification of cysteines. Mass
accuracy was set to 20 ppm for precursor ions and 1.0 Da for fragment ions. In GlycoPep
Scorer, the O-glycan composition (in the form of [SA]n[Hex]n[HexNAc]n) and
glycosylation site were entered for each candidate. In Protein Prospector, O-glycans were set
as variable modifications on Ser and Thr residues in the form of HexNAc, Hex1HexNAc,
SA1HexNAc, SA1Hex1HexNAc or SA2Hex1HexNAc. All glycopeptide identifications were
manually inspected to determine the false-discovery rates.
RESULTS AND DISCUSSION
Fetuin and the HIV Env glycoprotein, 1086.C gp120, are both N- and O-
glycosylated.32, 34-35 As a result, PNGase F was used to cleave the N-glycans off the
proteins prior to tryptic digestion. In this way N-linked glycopeptides would not interfere
with the analysis of O-linked glycopeptide data.20 For each O-glycopeptide studied, its
sequence, glycan composition and attachment site were confirmed based on prior knowledge
of the protein, combined with the MS and CID/ETD-MS/MS data. The ETD data were
specifically studied to discover distinct fragmentation patterns and to develop rules that can
aid in the identification of O-glycopeptides.
O-Glycopeptide Fragmentation Rules in ETD
O-glycopeptide ions with m/z values over 1200 generally did not produce enough peptide
fragments that could be used for sequencing. Below this value, c- and z-ions were frequently
recorded in ETD spectra for glycopeptides of 2+ and higher charge states, along with y-ions
and occasional peaks from glycan dissociations. However, the dominant fragment ion series
varied significantly for different precursor ions, and even O-glycopeptides with analogous
structures had distinct dissociation patterns. Figure 1A and 1B show the ETD-MS/MS data
of two isomeric glycopeptides from mucin that only differ in their O-glycosylation sites. For
the glycopeptide whose glycan attaches to Thr-3, c-ion series (c8-c14) are predominantly
present in its ETD spectrum while no z-ions are found (Figure 1A). This pattern contrasts
with the data from the Thr-13 glycosylated isomer, which generated both c- and z-ions
during ETD (Figure 1B). Even for the same glycopeptide species, the ETD fragmentation
may be drastically different if the charge state changes. The ETD spectra of an
erythropoietin O-glycopeptide with 2+ and 3+ charges are demonstrated in Figure 1C and
1D, respectively. The doubly charged precursor ion primarily dissociates into eight
dominant z-ions with only one single c-ion (c14) produced in the spectrum (Figure 1C). As
the glycopeptide carries more charges, however, its fragmentation efficiency in ETD
improves so that both c- and z-ion series of high sequence coverage are recorded (Figure
1D). An effective algorithm for scoring O-glycopeptide ETD data must be optimized to
score these types of spectra, where the fragment ion series is varied and unpredictable.
Therefore, fixed weightings for different ion types would most likely not work optimally.
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Furthermore, we discovered that for O-glycopeptides at 3+ or higher charge state, doubly
charged fragment ions were likely to appear in the high m/z end of the ETD spectra.
Example data are shown in Figure 2A and 2B, in which the precursor ions are two
glycopeptides from the HIV envelope glycoprotein, 1086.C gp120, with 3+ and 4+ charges.
For the glycopeptide in Figure 2A, the relatively large O-glycan modification (+1312.5 Da)
makes the c-ions (c12-c14) and z-ions (z7-z14) that contain the glycosylated Thr-12 too large
to be detected in the scan range of up to m/z 2000. Consequently, searching for these singly
charged fragment ions is not very useful for increasing the coverage of the glycopeptide
sequence, especially for z-ion series among which only two ions (z3 and z6) are found in the
spectrum. By considering doubly charged c2+- and z2+-ions whose singly charged
counterpart ions are beyond the mass range, the coverage of both c- and z-ion series are
increased, as two more c2+-ions and five z2+-ions are identified as shown in Figure 2A. The
same trend is observed in Figure 2B, where singly charged c-ions beyond c11 and z-ions
beyond z10 are not recorded due to their high m/z values. However, the extra five c2+-ions
(c122+-c162+) and z2+-ions (z102+ and z132+-z162+) provide extended sequence coverage for
the O-glycopeptide. The fragmentation of O-glycopeptides in ETD also differs from N-
linked glycopeptides significantly. As is illustrated in the ETD spectrum of a complex-type
N-glycopeptide from avidin (Figure 2C), only singly charged c- and z-ion series exist while
no c2+- or z2+-ions are generated except a single z162+ ion. In this circumstance,
incorporating doubly charged fragment ions into the search of c- and z-ions is not helpful for
identifying the correct glycopeptide composition, since it can lower the percentage of
matched fragment ions over the number of possible ions being searched, and the false
positive identifications would be increased.
An ETD spectrum of a mucin-type core-1 O-glycopeptide is present in Figure 3A. The most
significant spectral feature is that the major peaks in the ETD spectrum are unreacted
precursor ion, charge-reduced species and their neutral losses, which are not useful for
identifying the glycopeptide sequence. However, the peptide backbone fragment ions (c- and
z-ions) do exist in the data, as is illustrated in the two enlarged windows in Figure 3A, even
though their relative intensities are very low compared to the base peak. Moreover, by
comparing the two insets (m/z 300-500 v.s. m/z 1150-1350) in Figure 3A, it is found that
interfering peaks are not evenly populated along the m/z scale in the ETD spectrum. The low
m/z area has fewer peaks of noise even though the spectral intensity is low (normalized level
of 2.35×102), while abundant interfering peaks are present in the high m/z end with
relatively high intensity values (normalized level of 3.49×103). The trend is similar to what
has been observed for N-linked glycopeptides, where useful fragment ions need to be
differentiated from ETD side products and noise peaks.37
Algorithm Design and Implementation in O-glycopeptide ETD Data Analysis
After the key features of O-glycopeptide fragmentation in ETD were identified, an algorithm
was developed based on the characteristic fragmentation rules. First, we employed the
spectral preprocessing approach that was previously used for handling N-glycopeptide data
to filter noise peaks in the O-linked glycopeptide ETD spectra.37 Briefly, the precursor ion,
charge-reduced species and their neutral losses are removed. Subsequently, the spectrum is
split into two halves by the precursor m/z value: For the low m/z half, the 5 highest peaks in
every 100 Da bin are retained with other peaks removed; for the high m/z half, only the top 3
peaks are preserved in each bin. Finally, the retained peaks in the low m/z area are amplified
by a factor of 5. By this method, the fragment ion peaks of low m/z values and low intensity
(but good signal-to-noise ratio), as opposed to high noise peaks in the high m/z area, can be
preserved and given more weighting in the scoring process.
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After spectral filtering, the spectrum is then subjected to algorithm scoring. As is discussed
earlier, for O-glycopeptides, different types of peptide backbone fragment ions have large
deviations of sequence coverage in ETD, and one ion series that dominates a spectrum may
not be well represented in the other spectrum. As a result, in our designed algorithm,
different fragment ion series (c-, z- and y-ions) are separately searched and scored. In
addition, for O-glycopeptides at 3+ or higher charge state, doubly charged c2+- and z2+-ions,
of which the equivalent singly charged ions are beyond the scan range, are also incorporated
into the search of c- and z-ion series, thus taking advantage of the distinct O-glycopeptide
fragmentation pattern in ETD that doubly charged ions are frequently found in the high m/z
end of a spectrum. It should be noted that although programs used for analyzing peptide MS/
MS data also consider doubly charged fragment ions,38-40 our algorithm differs in that no
doubly charged ion present in the low m/z half of the spectrum is searched, because these
ions are typically not seen in the O-glycopeptide ETD data. Therefore, an individual score
corresponding to each ion type, is determined by the probability that a random sequence
would have the same or higher number of matched peaks as the input glycopeptide
candidate, using the following equation:
Herein, N is the total number of searched k-ions, and n is the number of matched k-ions to
the spectrum. In the next step, the weighting of each ion series is calculated by dividing the
intensities of spectral peaks matched to the specific ion type into the total intensities of all
matched peaks, and the total score of the candidate is then determined by summing up the
weighted individual scores of c-, z- and y-ion series:
A detailed description of the algorithm, including the spectral filtering and scoring method,
is contained in Supporting Information.
Algorithm Scoring of O-glycopeptide Candidate Compositions
As an example of using the algorithm in O-glycopeptide data analysis, the raw ETD
spectrum, as illustrated in Figure 3A, was scored against the correct glycopeptide candidate
of VVEIKPLGVAPTEAK (where T is modified with SA2Hex1HexNAc). After spectral
filtering, the processed spectrum is shown in Figure 3B, where peaks that are matched to
predicted fragment ions are labeled in color. The scoring parameters of all the ion series (c-,
z- and y-ions) are also listed in the inset of Figure 3B. For the correct candidate, 9 singly
charged c-ions and 3 doubly charged c2+-ions (starting from c122+ of m/z 1085) are searched
against the processed spectrum, and 7 out of the 12 c-ions searched are matched to the ETD
data. Consequently, for c-ion series, the probability that a random glycopeptide sequence has
seven or more c-ions matched in the spectrum, is calculated using the binomial distribution.
An individual score of 54.2 for c-ions is then determined by converting the probability into
the Log10 scale and multiplying by −10. Scores of z-ions and y-ions are computed in the
same way, except that for y-ions, no doubly charged species are considered because they are
not consistently produced. Subsequently, each ion series is weighted to calculate the total
score of the input candidate, and the weighting factor is proportional to the matched spectral
peaks’ intensities, as described in detail in the algorithm in Supporting Information. As is
shown in Figure 3B, multiple peaks assigned to c- and z-ions are dominant peaks in the
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processed spectrum, and large weightings of 54% and 45%, respectively, are given to these
two ion types automatically. In contrast, the y-ion series is only 1% weighted, since only
two y-ions are matched to spectral peaks of low intensity. A total score of 39.9 is then
determined by summing up the product of the individual ion series’ score and the weighting.
Clearly, we designed the algorithm with these novel weighting features because the
weighting for respective ion series varies according to the assigned spectral peaks, which is
ideal for the O-linked glycopeptide ETD data shown here. Even when one type of ions is
seriously underrepresented, that ion series’ score will not have a high impact in the total
score because its overall intensity level is low.
The correct glycopeptide composition, as illustrated in Figure 3B, was further corroborated
by the corresponding CID spectrum, which is shown in Figure 3C. The dominant peaks in
the CID data are intact peptides with sequential losses of monosaccharide units, and the
glycan portion can be deduced to be SA2Hex1HexNAc based on these fragment ions (Figure
3C).
To test whether the algorithm is effective in differentiating the correct O-glycopeptide
composition from multiple decoy candidates, the ETD data presented in Figure 3A, was
further scored against nine isobaric decoy compositions bearing identical or similar O-
glycan portions, and the result is summarized in Table 1. One can clearly see that the correct
glycopeptide composition received the highest score of 39.9, which is significantly higher
than other decoys. Among all the incorrect assignments, the glycopeptide candidate having
the sequence YKVVEIKPLGVAPTEAK (where T is attached to SA1Hex1HexNAc),
received the best score of 13.8. The slightly higher score for this candidate is expected,
because its sequence is highly homologous to the correct glycopeptide sequence. In this
case, the algorithm still works effectively to distinguish the true candidate from the incorrect
composition based on the ETD data even if their sequences are very similar.
Analysis of O-linked Glycopeptide ETD Data Sets by GlycoPep Scorer
We integrated the spectral preprocessing method and the designed scoring algorithm into a
standalone program, GlycoPep Scorer, and used the software to analyze the collected O-
glycopeptide ETD-MS/MS data from multiple glycoproteins including mucin, fetuin,
erythropoietin and the HIV envelope protein, 1086.C gp120. More than 40 ETD spectra
from 22 distinct O-glycopeptides were scored by the program, including 5 O-glycopeptide
species that have more than one potential glycosylation site of Ser or Thr. For every tested
ETD spectrum, site-specific assignment of the corresponding O-glycopeptide composition
was made correctly by GlycoPep Scorer, and the real glycopeptide was assigned a score at
least 1.5 times higher than other decoy candidates, including positional isomers where the
same peptide sequence and glycan portion are present, but the decoys differ from the correct
candidate only in the glycosylation site location. The scoring results of all glycopeptide
candidates using GlycoPep Scorer are summarized in Table S1 in Supporting Information.
To compare the performance of GlycoPep Scorer with other software, the same O-linked
glycopeptide ETD data sets were also analyzed by Protein Prospector. Since the possible
glycan modification is limited to simple O-glycan compositions, a subset of ETD spectra
collected from 16 distinct glycopeptides having glycan compositions of
SA0-2Hex0-1HexNAc, were subjected to Protein Prospector scoring. Table 2 lists the
comparison of the results from the two programs. For the 16 unique O-glycopeptide spectra
analyzed by Protein Prospector, 3 glycopeptide compositions were incorrectly assigned. In
contrast, no decoy glycopeptide composition received a higher score than the correct
glycopeptide candidate in GlycoPep Scorer, both for the subset data where the O-glycan
conforms to the composition of SA0-2Hex0-1HexNAc, and for the whole data set, in which
the glycan has a composition of SA0-2Hex0-2HexNAc1-2. A full list of the test results for all
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glycopeptide compositions scored by GlycoPep Scorer and Protein Prospector, is provided
in Table S1 and S2, respectively, in Supporting Information. The peak lists from the ETD
spectra are also provided in Supporting Information. The average scores for the correct
composition and the best-matched decoy candidate given by both programs are presented in
Table 2. For Protein Prospector, the correct glycopeptide assignment receives an average
score of 44.7, and the highest decoy score averages at 29.7. A lager score difference is
observed in GlycoPep Scorer for the same subset data, in which the correct composition has
a score of 55.7 while the best-matched decoy composition has a score of 18.4. Although
direct comparison of the absolute score values would be inappropriate since the two
software’s algorithms are different, GlycoPep Scorer is demonstrated herein to be
efficacious in assigning site-specific O-glycopeptides accurately by analyzing the ETD data.
Additionally, the larger score difference between the correct and incorrect assignment in
GlycoPep Scorer provides more confidence that the highest scoring candidate is the right
glycopeptide composition. The superior performance of the program in turn proves the
advantage of using our spectral filtering approach and a scoring algorithm designed
specifically for fragmentation of O-linked glycopeptides. At the current stage, the
glycopeptide candidates need to be input manually into GlycoPep Scorer, which is probably
the key drawback to using the software in its current format. However, the algorithm for
scoring O-linked glycopeptides could be incorporated into any other glycopeptide scoring
tool which uses a more automated workflow; in doing so, the convenience of automation
could be combined with the power of a highly tuned scoring system.
CONCLUSIONS
We studied the fragmentation of O-linked glycopeptides in ETD and identified their
characteristic spectral features that can be applied into data analysis automation. For O-
glycopeptides, the dominant ion series varies with different precursor ions, and it is not
uncommon to see the phenomenon that one type of ion series is much more abundant than
other ion types in ETD. Furthermore, we found that doubly charged c2+- and z2+-ions are
often recorded in the high m/z half of the spectra for highly charged glycopeptides, and these
ions can be included into the search of c- and z-ion series to substitute the singly charged c-
and z-ions of which the m/z values are above the mass limit. In this way the sequence
coverage is increased, and the individual scores of each ion series are not undermined by a
lack of doubly charged ions in the low m/z end.
By correlating the weighting for each type of ions with the intensity of matched peaks, we
developed an algorithm that uses O-glycopeptide fragmentation patterns to score the
potential glycopeptide compositions against the ETD data. The algorithm, along with a
spectral filtering method, was combined into the GlycoPep Scorer program, which was used
in data analysis of O-glycopeptide ETD-MS/MS spectra. The program was able to determine
the site-specific O-glycopeptide composition correctly with no false positives, and the large
score differences between the true and decoy candidates demonstrate the benefit of the
algorithm in interpreting glycopeptide ETD data. The fragmentation rules and algorithm in
this study can be widely applied into other computer programs for identifying O-
glycopeptides and determining the modification site on a large scale.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
ETD-MS/MS data from (A) a mucin O-linked glycopeptide of which the glycan is attached
to the Thr-3 residue (2+, m/z 852.9); (B) an isomeric O-glycopeptide of (A) that has the
same composition but with a different modification site at Thr-13 (2+, m/z 852.9); (C) a
doubly charged O-glycopeptide from erythropoietin with the Ser-10 residue glycosylated
(m/z 834.9); (D) the same glycopeptide as (C) but at 3+ charge state (m/z 557.0). Peptide
backbone fragment ions (c-, z- and y-ions) are labeled in different colors as shown in the
figure. Glycan symbols used herein and in the following figures include N-acetylhexosamine
(yellow and blue squares, HexNAc), hexose (yellow and green circles, Hex), and sialic acid
(purple diamond, SA).
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Figure 2.
ETD spectra of (A) an O-linked core-2-type glycopeptide (3+, m/z 955.1) and (B) a core-1-
type O-glycopeptide (4+, m/z 696.6) from the HIV envelope glycoprotein, and (C) a hybrid-
type N-linked glycopeptide (3+, 1153.5) from avidin.
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Figure 3.
(A) ETD-MS/MS data of an O-linked glycopeptide (3+, m/z 833.4) with its composition
shown in (B), note that two enlarged windows showing the zoomed m/z regions of 300-500
and of 1150-1350, respectively are also present in the figure; (B) processed ETD data of (A)
after spectral filtering to remove noise peaks, and the inset table lists the scoring results
(including the individual ion series’ scores and the respective weightings) of the correct
glycopeptide composition against the processed data; (C) CID-MS/MS data of the same
glycopeptide as shown in (B).
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Table 1
Algorithm scoring results of the ETD-MS/MS data against 10 O-glycopeptide compositionsa
Candidate Mass O-linked Glycopeptide Compositionsb Total Score
Correct 2497.2309 VVEIKPLGVAPTEAK + SA2Hex1HexNAc 39.9
Decoy 1 2497.2930 YKVVEIKPLGVAPTEAK + SA1Hex1HexNAc 13.8
Decoy 2 2497.2013 DFAGITGAYGAVAAGASFLFAR + Hex1HexNAc 10.0
Decoy 3 2497.2224 YLTAPTITSGGNPPAFSLTSDGK + HexNAc 8.1
Decoy 4 2497.2057 ATIIVHLNESVNIK + SA2Hex1HexNAc 6.3
Decoy 5 2497.2309 AETPAVGLPKIEVVK + SA2Hex1HexNAc 5.7
Decoy 6 2497.2210 LAIIQFISGNPLHK + SA2Hex1HexNAc 3.9
Decoy 7 2497.2516 TLFWTAVFLTIIGFGR + SA1Hex1HexNAc 3.4
Decoy 8 2497.2356 INSLVACGENINALLIK + SA1Hex1HexNAc 3.1
Decoy 9 2497.2422 GDNLLPAIVGLSILR + SA2Hex1HexNAc 1.9
a
The ETD spectrum is shown in Figure 3A.
b
The O-glycosylation sites are labeled in red, and the monoisotopic masses of the listed glycopeptide candidates are within 20 ppm mass error.
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Table 2
Analysis summary of GlycoPep Scorer and Protein Prospector in interpreting O-glycopeptide ETD datasets
Program Name False Positives Correct Score Best Decoy Score
Protein Prospectora
(O-glycan: SA0-2Gal0-1GalNAc1)
3/16 44.7 29.7
GlycoPep Detectora
(O-glycan: SA0-2Gal0-1GalNAc1)
0/16 55.7 18.4
GlycoPep Detectorb
(O-glycan: SA0-2Gal0-2GalNAc1-2)
0/22 53.0 18.3
a
False positives and average scores were based on the scoring of a subset of 16 distinct ETD spectra collected from O-glycopeptides bearing
glycan compositions of SA0-2Gal0-1GalNAc1.
b
False positives and average scores were based on the scoring of a total of 22 ETD spectra collected from O-glycopeptides bearing glycan
compositions of SA0-2Gal0-2GalNAc1-2.
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